Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
Open Access
- 20 October 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 118 (16), 4346-4352
- https://doi.org/10.1182/blood-2011-01-330738
Abstract
Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest benefit is seen in those patients achieving a hematologic complete response (CR). We analyzed a series of 421 consecutive patients treated with HDM/SCT at a single referral center and compared outcomes for patients with and without CR. Treatment-related mortality was 11.4% overall (5.6% in the last 5 years). By intention-to-treat analysis, the CR rate was 34% and the median event-free survival (EFS) and overall survival (OS) were 2.6 and 6.3 years, respectively. Eighty-one patients died within the first year after HDM/SCT and were not evaluable for hematologic and organ response. Of 340 evaluable patients, 43% achieved CR and 78% of them experienced an organ response. For CR patients, median EFS and OS were 8.3 and 13.2 years, respectively. Among the 195 patients who did not obtain CR, 52% achieved an organ response, and their median EFS and OS were 2 and 5.9 years, respectively. Thus, treatment of selected AL patients with HDM/SCT resulted in a high organ response rate and long OS, even for those patients who did not achieve CR.Keywords
This publication has 37 references indexed in Scilit:
- Amyloidosis: Pathogenesis and New Therapeutic OptionsJournal of Clinical Oncology, 2011
- Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006Bone Marrow Transplantation, 2010
- Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) AmyloidosisJournal of Clinical Oncology, 2010
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantationBlood, 2007
- High-Dose Melphalan versus Melphalan plus Dexamethasone for AL AmyloidosisNew England Journal of Medicine, 2007
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and AmyloidosisAmerican Journal of Hematology, 2005
- Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcomeBone Marrow Transplantation, 2003
- Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patientsBritish Journal of Haematology, 1998
- 352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence DataBiometrics, 1973
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958